Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

More documents

Recommendations

Info

396 Index ±, tumor 224 ±, tumor-associated 231ff. antileukemia effect, HSV-tk engineered donor lymphocytes 305 antinuclear antibodies 194 antiserum, anti-asialo-GM1 274 anti-Tac(Fv)-PE38 (LMB-2), immunotoxins 362, 368 antithyroid antibodies 194 antitumor immunity, models 205 antitumor response, MHC class II expression 82f. antitumor vaccination 218±221 APCs see antigen-presenting cells APM see antigen-processing machinery apoptosis ±, DCs 105 ±, effects of polyamines 133 ±, immunotoxins 351 ±, NK cells 101 ±, T cell 123 ±, T lymphocyte 111 ±, tumor-induced see tumor-induced apoptosis apoptotic bodies, dendritic cells 187 arthritis, rheumatoid 215 autoantigens ±, cancer-related 22 ±, non-cancer-related 23 autoimmune disease 209, 222 ±, antigen presentation 211 ±, genetic linkages 215f. autoimmune-like reactivity 221 autoimmune reactions 51, 194, 232, 235 autoimmunity 214±217 autologous HSPs 256ff. b B cell leukemias 362 B cell lymphomas 17, 347 B cells ±, bacterial immunotherapy 272ff. ±, HCV 238 ±, lysis by hTERT specific CTL 10 ±, tumor microenvironment 108 Bacillus Calmette-Guerin (BCG), cancer immunotherapy 268f. backbone, ODN classes 272ff. bacterial DNA, cancer immunotherapy 268±286 bacterial extracts, cancer immunotherapy 268ff. bacterial immunotherapy 268±286 bacterial toxins 352ff. BCG see Bacillus Calmette-Guerin BCG treatment 215 Bcr-Abl junction 211 bDNA see bacterial DNA b subunits of 20S proteasome 31±34, 69ff. b2-m gene 67ff. biological activities, IL-10 157±161 Birbeck granules 180 bladder cancer, bacterial immunotherapy 268 blood DCs 180, 183±186 BMT see bone marrow transplantation bone marrow, immunocytokines 337f. bone marrow transplantation (BMT), immune therapy 299±310 breast cancer 361 ±, clinical trials 190 ±, immunotoxins 360 c CAMEL, antigen 48 cancer ±, bladder see bladder cancer ±, breast see breast cancer ±, CEA expressing see CEA expressing cancer ±, colon see colon cancer ±, gastro-intestinal see gastro-intestinal cancer ±, human see human cancer ±, ovarian see ovarian cancer ±, pancreas see pancreas cancer ±, prostate see prostate cancer ±, renal cell see renal cell cancers ±, see also carcinoma ±, see also tumors cancer genomics 10 cancer immunology, strategies 177±379 cancer immunome 24f. cancer immunosurveillance 204 cancer models, effects of IL-10 164 cancer patients, IL-10 expression 161±164 cancer-specific antibodies 290 cancer vaccination, dendritic cells 179±203 cancer vaccine, preventative 12 cancer vaccine development 25f. carbohydrate antigen Lewis Y (LeY) 347, 367 ±, immunotoxin therapy 360 carbohydrates, complex 354 carcinoembryonic antigen (CEA) 135 ±, immunocytokines 319±327 carcinoma ±, colon see colon carcinoma ±, colorectal see colorectal carcinoma ±, ovarian see ovarian carcinoma ±, prostate see prostate carcinoma ±, see also cancer
±, see also tumors cationic lipids, bacterial immunotherapy 274 CD3 z chain 102, 288 CD4 helper T lymphocyte responses 195 CD4 T cell help, definition 223 CD4 T cells 49ff., 79, 81ff., 99ff. ±, effects of IL-10 127, 159f. ±, immunocytokines 320, 331f., 335f. CD8 T cells 99ff. ±, effects of IL-10 127 ±, immunocytokines 330ff., 335f., 338ff. CD8 + cytotoxic T lymphocytes 232, 304, 315± 318 ±, see also cytotoxic T lymphocytes (CTL) CD19 antigen 347 CD20 antigen 347 CD22 antigen 347, 361f. CD25 361f. CD28 T cells, T-body approach 289 CD40 322ff., 332 CD54 see intercellular adhesion molecule CD80 326 ±, tumor microenvironment 110ff. CD95-CD95 (CD95L) ligand pathway see also FasL Pathway CD123 DCs, lymphoid 180f., 183 CDR see complementary-determining region CEA see carcinoembryonic antigen CEA expressing cancer, clinical trials 191 CEA/CD40 ligand trimer 322 cell damage, immunotoxins 367 cell death 211±214, 218±221 ±, activation-induced 234 cell differentiation, polyamines 133 cell interaction, HCV 234 cell killing, tumor 218f. central tolerance ±, antigen presentation 211 ±, definition 223 C g1 gene 312 ch14.18, immunocytokines see human/mouse antiganglioside GD2 antibody ch14.18-IL-2 fusion protein, immunocytokines 330±341 ch14.18-LT-a immunocytokine 333f. chaperons, HSPs 254f. chemical conjugate immunotoxins see firstgeneration immunotoxins chemokines, effects of dendritic cells 181 chemotherapy 299 chimeric receptors (CRs) 288±295 chimeric toxins 350 chromium release assay, CTL monitoring 45 chronic myelogenous leukemia (CML) 301ff. Index chronic myeloid leukemia, clinical trials 189 CIITA see MHC class II transactivator class II-associated Ii peptide (CLIP) see MHC class II-associated Ii peptide clinical impact, HLA-G expression 88 clinical relevance, MHC class I alterations 76±79 clinical significance, antibody responses 23 clinical staging, GvHD 300 clinical trials ±, colateral carcinoma 293 ±, DC preparations 188±194 ±, HCV 238±241 ±, HIV 293 ±, HSPs 257f. ±, HSV-tk-transduced donor lymphocytes 304f. ±, hTERT 8±12 ±, huKS1/4-IL2 immunocytokine 329 ±, IL-10 therapy 167 ±, leukemia 361f. ±, ovarian carcinomas 294 ±, polynucleotides 270 ±, ricin-based immunoconjugates 361f. ±, RNA vaccination 187 ±, side effects of DC vaccinations 194 ±, T bodies 293f. ±, vaccination strategies 234f. CLIP see MHC class II-associated Ii peptide CML see chronic myelogenous leukemia CMV see cytomegalovirus Coley's toxins 268, 278 colon cancer, immunotoxins 360 colon carcinoma, immunocytokines 322ff. colorectal carcinoma ±, immunocytokines 313±316 ±, T-body approach 293 combinatorial peptide library approach 44 complementary-determining region (CDR)grafted antibodies 363, 366 complex carbohydrates 354 co-stimulatory molecules 210, 212ff. ±, definition 223 ±, HCV 236f. ±, T-body approach 289 counting, of DCs 183 COX inhibitors, prostaglandin (PG) E2 132 CpG-A and CpG-B classes of ODN 272±278 CpG DNA, usage of term 273 CpG motif receptors 271f. CpG motifs, from bacterial DNA 268±286 CRF2 see cytokine receptor family II cross-presentation ±, of peptides to thymic T cells 263 397
Page 1 and 2: Cancer Immune Therapie: Current and
Page 3 and 4: Editors: Dr. Gernot Stuhler Univers
Page 5 and 6: VI Preface Recent years have seen a
Page 7 and 8: VIII Contents 2.5.3 Antigens Encode
Page 9 and 10: X Contents 6.4.2 Natural Killer (NK
Page 11 and 12: XII Contents 9.6 Loading DC with An
Page 13 and 14: XIV Contents 14.2.2.1 Cancer-specif
Page 15 and 16: List of Contributors Richard Bucala
Page 17 and 18: Color Plates Fig. 5.2 The MHC class
Page 19 and 20: Fig. 5.5 Different immune effector
Page 21 and 22: Fig. 5.17 Possible pathway for the
Page 23 and 24: Fig. 6.2 T lymphocytes in the tumor
Page 25: Index a acidic and basic fibroblast
Page 29 and 30: e EBV see Epstein-Barr virus EDR se
Page 31 and 32: immature Mo-DCs 184 immune cells ±
Page 33 and 34: MHC class I antigen-processing mach
Page 35 and 36: ±, onco- 209 ±, over-expressed ce
Page 37 and 38: TICD see tumor-induced cell death T
Page 39 and 40: Part 1 Tumor Antigenicity Cancer Im
Page 41 and 42: 4 1 Search for Universal Tumor-Asso
Page 47 and 48: 10 1 Search for Universal Tumor-Ass
Page 55 and 56: 18 2 Serological Determinants On Tu
Page 67 and 68: 30 Cancer Immune Therapie: Current
Page 69 and 70: 32 3 Processing and Presentation of
Page 77 and 78:
40 Cancer Immune Therapie: Current
Page 79 and 80:
42 4 T Cells In Tumor Immunity cult
Page 81 and 82:
44 4 T Cells In Tumor Immunity cell
Page 83 and 84:
46 4 T Cells In Tumor Immunity to T
Page 85 and 86:
48 4 T Cells In Tumor Immunity Alth
Page 87 and 88:
50 4 T Cells In Tumor Immunity Tab.
Page 89 and 90:
52 4 T Cells In Tumor Immunity rest
Page 91 and 92:
54 4 T Cells In Tumor Immunity 53 T
Page 93 and 94:
Part 2 Immune Evasion and Suppressi
Page 95 and 96:
60 5 Major Histocompatibility Compl
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
68 Tab. 5.1 HLA class I loss attrib
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
96 6 Immune Cells in the Tumor Micr
Page 133 and 134:
98 6 Immune Cells in the Tumor Micr
Page 135 and 136:
100 6 Immune Cells in the Tumor Mic
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Tab. 7.1 Effects of tumor-derived m
Page 157 and 158:
122 7 Immunosuppresive Factors in C
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
156 8 Interleukin-10 in Cancer Immu
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Part 3 Strategies for Cancer Immuno
Page 213 and 214:
180 9 Dendritic Cells and Cancer: P
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
206 10 The Immune System in Cancer:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
232 11 Hybrid Cell Vaccination for
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
254 12 Principles and Strategies Em
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
270 13 Applications of CpG Motifs f
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
288 14 The T-Body Approach: Towards
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
300 15 Bone Marrow Transplantation
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
312 16 Immunocytokines: Versatile M
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
348 17 Immunotoxins and Recombinant
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
382 Glossary tion to the variable d
Page 417 and 418:
384 Glossary suppressor gene produc
Page 419 and 420:
386 Glossary press the proper recep
Page 421 and 422:
388 Glossary gp96 See Chaperone. Gr
Page 423 and 424:
390 Glossary cytes and addressing l
Page 425 and 426:
392 Glossary T bodies are being tes
show all

Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

Create successful ePaper yourself

Delete template?

Save as template?